Rhythm Pharmaceuticals Stock Net Income
| RYTM Stock | USD 56.12 0.64 1.15% |
Rhythm Pharmaceuticals fundamentals help investors to digest information that contributes to Rhythm Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rhythm Stock. The fundamental analysis module provides a way to measure Rhythm Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rhythm Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -184.7 M | -175.4 M | |
| Net Loss | -185.5 M | -176.3 M | |
| Net Loss | -163 M | -154.9 M | |
| Net Loss | (3.20) | (3.36) | |
| Net Income Per E B T | 1.00 | 0.78 |
Rhythm | Net Income |
Rhythm Pharmaceuticals Company Net Income Analysis
Rhythm Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Rhythm Pharmaceuticals Net Income | (184.68 M) |
Most of Rhythm Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rhythm Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rhythm Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rhythm Pharmaceuticals is extremely important. It helps to project a fair market value of Rhythm Stock properly, considering its historical fundamentals such as Net Income. Since Rhythm Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rhythm Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rhythm Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rhythm Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rhythm Pharmaceuticals reported net income of (184.68 Million). This is 154.11% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 132.34% higher than that of the company.
Rhythm Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rhythm Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics of similar companies.Rhythm Pharmaceuticals is currently under evaluation in net income category among its peers.
Rhythm Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rhythm Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rhythm Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rhythm Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rhythm Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rhythm Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rhythm Pharmaceuticals' value.| Shares | Driehaus Capital Management Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Rock Springs Capital Management Lp | 2024-09-30 | 1.2 M | Alkeon Capital Management, Llc | 2024-09-30 | 1.2 M | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 1.1 M | Checkpoint Capital Lp | 2024-09-30 | 663.4 K | Commodore Capital Lp | 2024-09-30 | 650 K | Loomis, Sayles & Company Lp | 2024-09-30 | 636.6 K | Hood River Capital Management Llc | 2024-09-30 | 614.6 K | Primecap Management Company | 2024-09-30 | 7.2 M | Blackrock Inc | 2024-06-30 | 6.7 M |
Rhythm Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.15 B | ||||
| Shares Outstanding | 61.46 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 99.48 % | ||||
| Number Of Shares Shorted | 6.37 M | ||||
| Price To Book | 307.53 X | ||||
| Price To Sales | 30.65 X | ||||
| Revenue | 77.43 M | ||||
| Gross Profit | 21.5 M | ||||
| EBITDA | (168.46 M) | ||||
| Net Income | (184.68 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 1.26 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (136.16 M) | ||||
| Short Ratio | 9.25 X | ||||
| Earnings Per Share | (4.32) X | ||||
| Price To Earnings To Growth | 0.75 X | ||||
| Target Price | 72.82 | ||||
| Number Of Employees | 226 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 3.45 B | ||||
| Total Asset | 332.75 M | ||||
| Retained Earnings | (894.74 M) | ||||
| Working Capital | 253.06 M | ||||
| Net Asset | 332.75 M |
About Rhythm Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rhythm Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Rhythm Pharmaceuticals Piotroski F Score and Rhythm Pharmaceuticals Altman Z Score analysis. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.